Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ciba-Geigy
|
| gptkbp:activities |
inhibits osteoclast-mediated bone resorption
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2000
gptkb:FDA |
| gptkbp:clinical_trial |
Phase III
less than 1% long-term management of osteoporosis treatment of glucocorticoid-induced osteoporosis |
| gptkbp:contraindication |
severe renal impairment
hypocalcemia esophageal abnormalities |
| gptkbp:dosage_form |
gptkb:tablet
150 mg tablet 35 mg tablet |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
risedronate sodium
|
| https://www.w3.org/2000/01/rdf-schema#label |
Actonel
|
| gptkbp:indication |
treatment of Paget's disease
prevention of osteoporosis |
| gptkbp:ingredients |
risedronate
|
| gptkbp:interacts_with |
antacids
calcium supplements nonsteroidal anti-inflammatory drugs (NSAI Ds) |
| gptkbp:invention |
gptkb:2018
|
| gptkbp:is_monitored_by |
renal function
bone density calcium levels |
| gptkbp:is_used_for |
treatment of osteoporosis
|
| gptkbp:lifespan |
approximately 1 hour
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:video_game_series
|
| gptkbp:marketed_as |
Actonel 150 mg
Actonel 35 mg |
| gptkbp:packaging |
blister pack
|
| gptkbp:safety_features |
risk of osteonecrosis of the jaw
risk of severe allergic reactions risk of atypical femur fractures |
| gptkbp:scholarships |
take on an empty stomach
remain upright for at least 30 minutes after taking |
| gptkbp:side_effect |
nausea
abdominal pain diarrhea |
| gptkbp:storage |
room temperature
|